Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hadas Nicole R.						2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [ AKBA ]									5. Relationship of Reporting Person(s) to (Check all applicable)  Director 10%				vner	
(Last)	ist) (First) (Middle) O AKEBIA THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 05/13/2024									X	belov	er (give title v) VP, Chief		Other (s below)	specify	
245 FIRST STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line)	· '					
(Street) CAMBRIDGE MA 02142															Form filed by One Reporting Person  Form filed by More than One Reporting  Person				- 1	
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution		ution D	ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			l and Securi Benefi Owned		cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or Pi	rice		ection(s) 3 and 4)			(Instr. 4)		
Common Stock 05/13/20					024				S		12,016(1)(2)		9	\$1.26	6 651,243			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\)		ate	7. Title and Amount of Securities Underlying Derivative Security (Ir 3 and 4)		De Se (In:	Price of ivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Shares	er							

## **Explanation of Responses:**

- 1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on
- 2. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

## Remarks:

/s/ Carolyn Rucci, attorney-infact for Nicole R. Hadas

\*\* Signature of Reporting Person

05/14/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.